

APASL Single Topic Conference in Yokohama "HCC: Strategy in the New Era"
Scientific Program

Pre-Conference Educations

Friday, May 11, 2018
Room 1 (301+302)
Pre-Conference Education 1
Epidemiology and Natural History of HCC-1
Chairs: Barjesh C. Sharma, Osamu Yokosuka

8:00-8:15	Epidemiology and Natural History of HCC in Japan	Yoshiyuki Ueno
8:15-8:30	Epidemiology and Natural History of HCC in Korea	Hong Soo Kim
8:30-8:45	Epidemiology and Natural History of HCC in China	Lai Wei
8:45-9:00	Epidemiology and Natural History of HCC in Mongolia	Oidov Baatarkhuu
9:00-9:15	Epidemiology and Natural History of HCC in Philippines	Diana A. Payawal
9:15-9:30	Epidemiology and Natural History of HCC in Indonesia	Laurentius A. Lesmana
9:30-9:45	Epidemiology and Natural History of HCC in Turkey	Necati Ormeci
9:45-9:55	Discussion	

Friday, May 11, 2018
Room 2 (304)
Pre-Conference Education 2
Liver Fibrosis and HCC
Chairs: Yoichi Hiasa, Yasuharu Imai

8:00-8:20	Liver Fibrosis and Development and Recurrence of HCC: Japanese Perspective	Hiroko Iijima
8:20-8:40	Liver Fibrosis and Development and Recurrence of HCC: Chinese Perspective	Xiaoyan Xie
8:40-9:00	Non-Invasive Evaluation of Liver Fibrosis by Serum Markers	Hiroshi Yatsunami
9:00-9:20	Non-Invasive Evaluation of Liver Fibrosis by Magnetic Resonance Imaging (MR Elastography)	Shigehiro Kokubu
9:20-9:40	Non-Invasive Evaluation of Liver Fibrosis by Ultrasonography (Elastography)	Kentaro Yoshioka
9:40-9:50	Discussion	

Symposia

Friday, May 11, 2018
Room 1 (301+302)
Symposium 1
Hepatitis B and HCC
Chairs: Rosmawati Mohamed, Chung-Kwe Wang

10:10-10:30	Is it Possible to Eradicate Hepatitis B in the Near Future?	Naoya Kato
10:30-10:50	Hepatitis B - to Prevent HCC in Japan	Yoichi Hiasa
10:50-11:10	Prevention of HCC Development from HBV Infection	Hiroshi Yatsunami
11:10-11:30	Occurrence of HCC Related to Hepatitis B Virus Infection among Japanese Patients	Kentaro Yoshioka
11:30-11:50	Discussion	

Friday, May 11, 2018
Room 1 (301+302)
Symposium 2
Hepatitis C and HCC
Chairs: George Lau, Kazuaki Chayama

13:40-14:00	Does Eradication of HCV by DAAs Enhance HCC Development?	Hideyuki Toyoda
14:00-14:20	Does Eradication of HCV by DAAs Enhance HCC Development?	Hideyuki Tamai
14:20-14:40	Does Eradication of HCV by DAAs Enhance HCC Development?	Norifumi Kawada
14:40-15:00	Hepatitis C and HCC	Nobuyuki Enomoto
15:00-15:20	Hepatitis C and HCC	Tetsuo Takehara
15:20-15:30	Discussion	

Friday, May 11, 2018
Room 1 (301+302)
Symposium 3
HCC with Vascular Invasion: HAIC, Radiation Therapy, Surgery, or Sorafenib?
Chairs: Kwang-Hyub Han, Masatoshi Kudo

15:40-16:00	HAIC	Hiroaki Nagamatsu
16:00-16:20	Efficacy and Safety of Transarterial Radioembolization for HCC with Portal Vein Thrombosis	Si Hyun Bae
16:20-16:40	Does Radiation Therapy Have a Role in HCC with Vascular Invasion?	Jinsil Seong
16:40-17:00	Survival Benefit of Liver Resection for HCC with Vascular Invasion	Norihiro Kokudo
17:00-17:20	HCC with Vascular Invasion: Systemic Therapy: Sorafenib and Beyond	Ann-Lii Cheng
17:20-17:30	Discussion	

Friday, May 11, 2018
Room 2 (304)
Symposium 4
Cost-Effectiveness of Treatments for HCC
Chairs: Norihiro Kokudo, Ryosuke Tateishi

10:10-10:30	Cost-Effectiveness of Molecular Targeting Agents for Advanced Stage of HCC	Namiki Izumi
10:30-10:50	Cost-Effectiveness of Hepatectomy and RFA for Initial Treatment of HCC: A Markov Model Analysis	Masaya Sato
10:50-11:10	Cost-Effectiveness of Transcatheter Arterial Therapy for the Treatment of Unresectable HCC	Haruyuki Takaki
11:10-11:30	Surgery (Hepatectomy)	Kiyoshi Hasegawa
11:30-11:50	Discussion	

Friday, May 11, 2018
Room 2 (304)
Symposium 5
Obesity and HCC
Chairs: A. Kadir Dokmeci, Hiromasa Ohira

15:40-15:55	Will NASH be a Major Etiology of HCC in Future?	Kenichi Ikejima
15:55-16:10	Will NASH be a Major Etiology of HCC in Future?	Rino Gani
16:10-16:25	The Relationship between Obesity and Hepatocarcinogenesis	Takamasa Ohki
16:25-16:40	Radiofrequency Ablation for Obese Patients with HCC	Koji Uchino
16:40-16:55	Surgery for Obese Patients with HCC	Minoru Tanabe
16:55-17:10	Obesity and HCC Development, Recurrence	Jin Mo Yang
17:10-17:30	Discussion	

Saturday, May 12, 2018
Room 1 (301+302)
Symposium 6
Current Status and Future Direction of Systemic Therapies for Advanced HCC
Chairs: Stephen L. Chan, Junji Furuse

9:10-9:30	First-line Chemotherapy for Advanced HCC	Masafumi Ikeda
9:30-9:50	Second-line Chemotherapy for HCC (Exclude Immunotherapy)	Kazuomi Ueshima
9:50-10:10	Immunotherapy for HCC	Stephen L. Chan
10:10-10:20	Discussion	

Saturday, May 12, 2018
Room 1 (301+302)
Symposium 7
What Do We Need to Know Before Ablation?
Chairs: Yi-You Chiou, Seiji Kawasaki

10:30-10:50	Pathology of Small HCC	Osamu Nakashima
10:50-11:10	Innovation in US for HCC	Takashi Nishimura
11:10-11:30	Microcirculation in HCC: CT/Pathologic	Osamu Matsui
11:30-11:50	Principle of Ablation for HCC	Masatoshi Tanaka
11:50-12:00	Discussion	

Saturday, May 12, 2018
Room 2 (304)
Symposium 8
Aging Society and HCC: Up to What Age Do We Consider Treating Patients with HCC in General?
Chairs: Massimo Colombo, Tadatoshi Takayama

10:10-10:30	Impact of Advanced Age on Survival in Patients Undergoing Resection of HCC: Report of a Japanese Nationwide Survey	Masaki Kaibori
10:30-10:50	Ablation Therapy for Elderly HCC Patients	Ryosuke Tateishi
10:50-11:10	Vascular Intervention	Takuji Torimura
11:10-11:30	Molecular Targeted Therapy for HCC	Masatoshi Kudo
11:30-11:50	Liver Transplantation; Physical Age is More Important than Chronological Age	Toshimi Kaido
11:50-12:00	Discussion	

Saturday, May 12, 2018
Room 3 (311+312)
Symposium 9
Epidemiology and Natural History of HCC-2
Chairs: Amarsanaa Jazag, Soo Ryang Kim

8:00-8:15	Epidemiology and Natural History of HCC in Vietnam	Le Lam Ngo
8:15-8:30	Epidemiology and Natural History of HCC in Myanmar	Khin Maung Win
8:30-8:45	Epidemiology and Natural History of HCC in Malaysia	Rosmawati Mohamed
8:45-9:00	Epidemiology and Natural History of HCC in Taiwan	Chia Yen Dai
9:00-9:15	Epidemiology and Natural History of HCC in Bangladesh	SMF Akbar
9:15-9:30	Epidemiology and Natural History of HCC in Kazakhstan	Amina Bulatihan
9:30-9:45	Epidemiology and Natural History of HCC in Nepal	Ananta Shrestha
9:45-10:00	Epidemiology and Natural History of HCC in Russia	Botvinkin Aleksandr
10:00-10:20	Discussion	

Saturday, May 12, 2018

Room 3 (311+312)

Symposium 10

Current Status and Future Direction of Therapies for Colorectal Liver Metastasis

Chairs: Kai-Wen Huang, Shunsuke Kato

10:30-10:50	Actual 10-year Survival after Surgical Resection of Colorectal Liver Metastases	Akio Saiura
10:50-11:10	Radiofrequency Ablation for Liver Metastasis from Colorectal Cancer	Takuma Teratani
11:10-11:30	Transarterial Treatment for Unresectable Colorectal Liver Metastasis	Yoshitaka Inaba
11:30-11:50	Chemotherapy	Kentaro Yamazaki
11:50-12:00	Discussion	

Sunday, May 13, 2018

Room 2 (304)

Symposium 11

Education in Hepatology

Chairs: Ming Kuang, Mitsuhiro Moriyama

10:20-10:40	Juntendo RFA Training Program	Shuichiro Shiina
10:40-11:00	ACTA School	Uei Pua
11:00-11:20	Development of HCC Network in Asia: Role of APASL	Shiv K. Sarin
11:20-11:40	Discussion	